Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases. Issue 12 (25th April 2019)

• Record Type: Journal Article
• Authors: Bick, David; Jones, Marilyn; Taylor, Stacie L; Taft, Ryan J; Belmont, John
• Is Part Of: Journal of medical genetics. Volume 56:Issue 12(2019)
• Page Start: 783
• Page End: 791
• Publication Date: 2019-04-25
• Subjects: clinical genome sequencing -- rare and undiagnosed -- genetic testing -- neonates -- pediatric; Medical genetics -- Periodicals; 616.042
• DOI: 10.1136/jmedgenet-2019-106111
• Languages: English
• ISSNs: 1468-6244

Abstract

Abstract : Up to 350 million people worldwide suffer from a rare disease, and while the individual diseases are rare, in aggregate they represent a substantial challenge to global health systems. The majority of rare disorders are genetic in origin, with children under the age of five disproportionately affected. As these conditions are difficult to identify clinically, genetic and genomic testing have become the backbone of diagnostic testing in this population. In the last 10 years, next-generation sequencing technologies have enabled testing of multiple disease genes simultaneously, ranging from targeted gene panels to exome sequencing (ES) and genome sequencing (GS). GS is quickly becoming a practical first-tier test, as cost decreases and performance improves. A growing number of studies demonstrate that GS can detect an unparalleled range of pathogenic abnormalities in a single laboratory workflow. GS has the potential to deliver unbiased, rapid and accurate molecular diagnoses to patients across diverse clinical indications and complex presentations. In this paper, we discuss clinical indications for testing and historical testing paradigms. Evidence supporting GS as a diagnostic tool is supported by superior genomic coverage, types of pathogenic variants detected, simpler laboratory workflow enabling shorter turnaround times, diagnostic and reanalysis yield, and impact on healthcare.